Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 101 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Locally Advanced Rectal Adenocarcinoma Clear all
Recruiting Phase 1 Interventional

Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial

NCT06834126
View directory record Official record
Conditions
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Consolidation Therapy, Functional Magnetic Resonance Imaging, Gastrointestinal Endoscopy, Magnetic Resonance Imaging, Papaverine, Radiation Therapy, Total Mesorectal Excision
Procedure · Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 2, 2026, 7:52 PM EDT
Not listed No phase listed Observational

Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer

NCT02877056
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Endoscopy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 2, 2026, 7:52 PM EDT
Completed Phase 2 Interventional

ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

NCT00030524
View directory record Official record
Conditions
Colorectal Cancer
Interventions
gefitinib
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 2, 2026, 7:52 PM EDT
Not yet recruiting Phase 2 Interventional

ctDNA-Informed Management of Early-Stage Rectal Cancer

NCT07209215
View directory record Official record
Conditions
Rectal Adenocarcinoma, Rectal Cancer, Early-stage Rectal Cancer, Locally Advanced Rectal Adenocarcinoma
Interventions
Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 2, 2026, 7:52 PM EDT
Recruiting Phase 2 Interventional

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

NCT04771520
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Locally Advanced Primary Malignant Central Nervous System Neoplasm, Locally Advanced Sarcoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Primary Malignant Central Nervous System Neoplasm, Metastatic Sarcoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Avapritinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 2, 2026, 7:52 PM EDT
Active, not recruiting Phase 2 Interventional

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

NCT04751370
View directory record Official record
Conditions
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Radiation Therapy, Sigmoidoscopy, Total Mesorectal Excision
Procedure · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
213
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 145 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 2, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer

NCT00613080
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, oxaliplatin, resection, radiation therapy, FOLFOX
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
119
States / cities
Mobile, Alabama • Auburn, California • Cameron Park, California + 94 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 2, 2026, 7:52 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05581004
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Interventions
Enzelkitug, Atezolizumab, Pembrolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
10
States / cities
San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 2, 2026, 7:52 PM EDT
Completed Phase 1 Interventional

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer

NCT00003799
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
fluorouracil, oxaliplatin, radiation therapy, leucovorin calcium, therapeutic conventional surgery
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 2, 2026, 7:52 PM EDT
Terminated Phase 1 Interventional

First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

NCT06625515
View directory record Official record
Conditions
Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer, Rectal Adenocarcinoma, Endometrial Cancer
Interventions
ATX-559
Drug
Lead sponsor
Accent Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 2, 2026, 7:52 PM EDT
Recruiting Phase 2 Interventional

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

NCT07281768
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Oxaliplatin, Capecitabine, Cemiplimab, Fianlimab, REGN7075
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 2, 2026, 7:52 PM EDT
Completed Phase 1Phase 2 Interventional

Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum

NCT00086931
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 2, 2026, 7:52 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

NCT06362369
View directory record Official record
Conditions
Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
Interventions
Alintegimod, Ipilimumab, Nivolumab
Drug
Lead sponsor
7 Hills Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 2, 2026, 7:52 PM EDT
Completed Phase 1Phase 2 Interventional

Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum

NCT00006094
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer
Interventions
oxaliplatin, fluorouracil, external beam radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 2, 2026, 7:52 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

NCT03422679
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma, Glomus Tumor, Malignant, Hepatocellular Carcinoma, Osteosarcoma, T-ALL
Interventions
CB-103
Drug
Lead sponsor
Cellestia Biotech AG
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Santa Monica, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 2, 2026, 7:52 PM EDT
Terminated Phase 2 Interventional Results available

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

NCT04644315
View directory record Official record
Conditions
Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Ovarian Neoplasms, Brain Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Salivary Gland Neoplasms, Head and Neck Neoplasms, Thyroid Cancer, Papillary, Lymphoma, Large-Cell, Anaplastic, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Central Nervous System
Interventions
Alectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
29
States / cities
Culver City, California • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 2, 2026, 7:52 PM EDT
Completed Phase 1 Interventional

Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer

NCT00084591
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2010 · Synced Oct 2, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

NCT02292758
View directory record Official record
Conditions
Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Bevacizumab, Cetuximab, Irinotecan, Laboratory Biomarker Analysis, Placebo
Biological · Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Scottsdale, Arizona • Boise, Idaho • Sioux City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 2, 2026, 7:52 PM EDT
Terminated Phase 2 Interventional Results available

Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

NCT00611858
View directory record Official record
Conditions
Rectal Cancer
Interventions
Cetuximab, 5-Fluorouracil, Radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Weymouth, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 2, 2026, 7:52 PM EDT
Terminated Phase 2 Interventional Results available

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

NCT05678257
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Neoplasm, Colorectal
Interventions
Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan, Bevacizumab, 5-FU
Drug · Biological
Lead sponsor
NuCana plc
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
16
States / cities
Newark, Delaware • Washington D.C., District of Columbia • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 2, 2026, 7:52 PM EDT
Active, not recruiting Early Phase 1 Interventional

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

NCT05108428
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Capecitabine, Radiation Therapy, FOLFOX regimen
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 2, 2026, 7:52 PM EDT
Terminated Phase 3 Interventional

Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer

NCT00070122
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
oxaliplatin, leucovorin calcium, capecitabine, bevacizumab, fluorouracil, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 2, 2026, 7:52 PM EDT
Completed Phase 2 Interventional

INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer

NCT04130854
View directory record Official record
Conditions
Locally Advanced Rectal Adenocarcinoma
Interventions
APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and Radiation Therapy 5Gy x 5 days
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Tucson, Arizona • Winston-Salem, North Carolina • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 2, 2026, 7:52 PM EDT
Terminated Phase 2 Interventional

SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

NCT00006001
View directory record Official record
Conditions
Colorectal Cancer
Interventions
semaxanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
10
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 2, 2026, 7:52 PM EDT